Reimbursement of long-term postplacement costs after endovascular abdominal aortic aneurysm repair  by Kim, Jason K. et al.
From the Society for Vascular Surgery
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and W. Charles Sternbergh III, MD,a New Orleans, La; and Scottsdale, Ariz
Objective: Postplacement cost of surveillance and secondary procedures over 5 years increases the global cost of
endovascular aortic aneurysm repair (EVAR) by nearly 50%. This study identified and assessed the reimbursement
received for long-term postplacement costs after EVAR.
Methods: Between December 1995 and June 2007, 360 patients underwent EVAR at a single institution. The reimburse-
ment collected from charges of postplacement surveillance and secondary procedures related to the aneurysmal disease
was evaluated and compared against the actual costs. All amounts were converted to year 2007 dollars. To minimize costs
associated with the early learning curve, the initial 50 EVAR patients between December 1995 and 1998 were excluded.
Patients with <1 year follow-up were also excluded. Data are expressed as mean  standard error.
Results: The mean follow up after EVAR for 152 patients was 38.8  1.8 months. Medicare, capitated insurance, and
commercial insurance provided coverage for 85 (56.0%), 49 (32.2%), and 18 (11.8%) patients, respectively. The
cumulative 5-year postplacement reimbursement received per patient was $9792 meeting 81.4% of the cumulative cost of
$12,027 for a net loss of $2235 per patient. Although 123 (80.9%) patients without secondary procedures generated a
5-year cumulative gain of $1830 per patient, 29 (19.1%) patients with secondary procedures averaged a 5-year cumulative
loss of $9378 per patient. The average reimbursement rate over the 5-year period was 35.8%  0.6%, with the lowest
reimbursement rate seen in patients with Medicare at 31.6%  0.7%.
Conclusion: Current reimbursement is not sufficient to meet the costs associated with long-term surveillance and needed
secondary procedures after EVAR. Inadequate reimbursement of costs associated with secondary procedures was the
primary driver for the net institutional loss. Reimbursement for outpatient radiological procedures generated a modest
surplus. ( J Vasc Surg 2008;48:1390-5.)Decreased perioperative morbidity and mortality of
endovascular abdominal aortic aneurysm repair (EVAR)
offers an attractive alternative to open surgical repair.1,2
However, the financial commitment involved with the high
cost of the endograft device and compulsatory long-term
surveillance may limit the widespread application of this
procedure as a cost-effective alternative.3,4 Initial enthusi-
asm that the cost savings from shortened operative time,
intensive care unit stay, and length of overall hospital stay
would compensate for the high endograft device cost has
been tempered by the failure of reimbursement to meet the
initial cost of EVAR.5-8 The noticeable increase in price of
endograft devices since the approval of their use in 1999 by
the US Food and Drug Administration further exacerbates
this disparity.8
The uncertainty of long-term durability of EVAR ne-
cessitates vigilant surveillance. Long-term postplacement
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1390surveillance, diagnostic studies, and possible secondary
procedures has been shown to increase the global cost of
EVAR by nearly 50%.9 However, the adequacy of reim-
bursement received for these costs remains unknown. This
study analyzed the reimbursement received for long-term
postplacement costs after EVAR from Medicare, capitated
insurance, and commercial insurance at a single institution.
METHODS
Between December 1995 and June 2007, 360 consec-
utive patients underwent EVAR of infrarenal aortic aneu-
rysms at the Ochsner Clinic Foundation (OCF). The first
50 patients undergoing EVAR from December 1995 to
December 1998 were excluded to minimize possible in-
creased costs associated with the learning curve. Patients
with less than 12 months of follow-up were also excluded.
The standard surveillance protocol after EVAR at OCF
during the study period consisted of an outpatient visit at 2
weeks, then 1, 6, and 12 months, and yearly thereafter. All
outpatient visits after the initial 2-week postoperative visit
included four-view plain abdominal radiographs (antero-
posterior, lateral, left and right oblique) and computed
tomography (CT) scan of the abdomen and pelvis with and
without intravenous contrast with 2.5 to 3.0 mm axial
images. Duplex ultrasonography was substituted for CT in
patients with renal insufficiency, defined as serum creati-
nine greater than 1.4 mg/dL. Noncontrasted CT scan was
not utilized. If a secondary procedure was performed, the
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yearly thereafter with surveillance studies at each visit.
Cost analysis and reimbursement. The method of
cost determination have been described previously.9 The
previously published cost data has been updated for this
report and the steps in our cost accounting system are
briefly described here. Direct expenses are first consolidated
monthly at a departmental (cost center) level and then are
classified by the cost components of labor, supply, equip-
ment, and facility. Next, components are divided into fixed
expenses independent of patient volume and variable ex-
penses dependent on patient volume. Individual patients
are assigned cost codes for every chargeable service or
supply item. Departmental managers and Hospital Deci-
sion Support then develop allocation statistics (relative
value units) for each component of every cost code so that
a final cost can be assigned. Individual patient costs are the
sum of costs from each department utilized. The average
cost calculations from January to June 2007 were used to
adjust prior years’ costs for the sake of data uniformity.
Institutional overhead expenses, costs of professional
services including fees for anesthesia, radiology, and sur-
geon’s fees, and outpatient visits were also included in cost
determinations. Charges, including professional fees, were
calculated by using department specific cost-to-charge ra-
tios based on a fixed fee schedule. Costs for outpatient
appointments were determined by using a time-based for-
mula. Patient appointments were categorized as 10, 20,
and 30 minutes according to evaluation and management
codes. Outpatient department expenses were then allo-
cated by the time coded for the follow-up appointment.
Overhead costs for the institution were added to the
direct costs by a factor of 30% for each patient. This factor
has been uniformly decided on by Hospital Decision Sup-
port and varies 1% to 2% monthly. This method allows for
equitable distribution among patients: those patients with
higher overall cost absorb more overhead cost. Overhead
expense includes costs from departments not directly in-
volved in patient care (eg, housekeeping, computer tech-
nology, finance), equipment and facility depreciation, and
interest expense on borrowings.
All costs were converted to year 2007 dollars calculated
with a 3.5% yearly inflation rate. The costs, charges, and
reimbursement associated with the preoperative evaluation
and initial endograft placement and hospitalization were
excluded from the analysis. Only those costs incurred after
discharge from the original EVAR and the reimbursement
received for those costs were included in this study. Two
accounting software databases were utilized (Eclipsys TSC,
Atlanta, Ga; and Data Warehouse, Oracle, Redwood
Shores, Calif).
Payors were classified into one of three categories:
Medicare, capitated insurance, and commercial insurance.
Medicare reimbursement was dependent upon inpatient or
outpatient generated costs. For inpatient visits, reimburse-
ment was calculated by multiplying the OCF-specific hos-
pital base rate by the relative weight of the diagnostic
related groups (DRG) assigned to the patient. Hospitalbase rates are influenced by a number of factors, including
geographic location, local labor markets, rural or urban
hospital status, and teaching or nonteaching hospital des-
ignation.10 Additionally, Medicare compensates for hospi-
tals that serve a disproportional mix of indigent patients.
Unlike hospital base rates which can be influenced by
numerous factors, the DRG relative weights are set by
Medicare and do not change.
For outpatient visits and procedures, reimbursement
was calculated using a predetermined group of services
known as ambulatory payment classification (APC) groups.
Each APC organized patients into separate categories based
on similar clinical characteristics and utilization of similar
types and amounts of resources at similar costs, and was
associated with a status indicator, payment rate, relative
weight, national unadjusted coinsurance amount, and min-
imum unadjusted coinsurance amount.11 The relative
weight was calculated on the basis of median cost of the
services included in the APC group and the payment rate
applied to all services bundled under the APC.
In contrast to Medicare’s inpatient prospective pay-
ment system, which assigns a single DRG to each patient
visit, the outpatient system may assign multiple APCs to a
single visit. If a patient undergoes multiple unrelated sig-
nificant procedures on the same day, separate APCs may be
assigned, but the APC with the highest payment will be
paid in full, with the remaining APCs reimbursed at a
discounted rate. Multiple related procedures are assigned
only one APC. None of the patients requiring secondary
procedures within the study cohort had additional unre-
lated secondary procedures on the same outpatient visit
that qualified to be billed with a separate, discounted APC.
Capitated insurance was defined as any insurance con-
tract where the hospital received a prenegotiated and fixed
stipend per month to encompass the global cost of that
patient’s care independent of the number of services uti-
lized. To calculate the actual total reimbursement received
per patient per year, the year-specific reimbursement rate
was first identified by dividing the cumulative prenegoti-
ated stipend received for that year by the total submitted
charges. This reimbursement rate was then applied to each
individual charge during that fiscal year to calculate the
patient-specific reimbursement amount received per proce-
dure.
Commercial insurance included all private health insur-
ance plan providers, including for-profit and not-for-profit
organizations. Reimbursement was predetermined by an
annually negotiated contract rate established by OCF with
each individual payor.
No patients in this study cohort had Armed Forces
related coverage (TRICARE). The one uninsured private-
pay patient in this cohort arranged a private contract with
OCF and was included in the commercial insurance group.
Definitions. A secondary procedure was defined as
any intervention (including diagnostic angiograms) per-
formed due to the original aneurysm or for a complication
of EVAR during the follow-up period.
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side the endograft. The types of endoleak have been de-
scribed previously.12,13 Indications for secondary proce-
dures were the presence of a type I or type III endoleak, or
a type II endoleak with significant aneurysm sac expansion
(5 mm).
Statistical analysis. The data are expressed as mean
standard error. P  .05 was considered statistically signifi-
cant. Continuous variables were compared between groups
using the unpaired Student t test and analysis of variance
(ANOVA) methods. Statistical analysis was performed us-
ing SAS software, version 9.1 (SAS Institute Inc, Cary,
NC).
RESULTS
Three-hundred and ten patients were treated with
EVAR in the study period. Reasons for exclusion from the
study included perioperative death (n  2), incomplete
reimbursement data (n  3), follow-up at another institu-
tion (n 16), patients who refused further follow-up (n
12), and less than 1 year of follow-up (n  125). These
exclusions left a patient cohort of 152 patients.
The mean follow-up was 38.8  1.8 months. Sixty-
seven of 152 patients were compliant with all of their
recommended outpatient visits and follow-up imaging.
One or more outpatient radiologic studies were missed by
65 patients, and 57 patients missed one or more outpatient
visits. Overall, 88.1% of outpatient visits and 84.1% of
radiological imaging studies were completed. Greater than
1-year lapse between follow-up visits occurred in 20 pa-
tients (mean 17.4  2.2 months).
The mean age of patients was 73.0 0.6 years. Spinal/
regional anesthesia was used in 126 of 152 patients
(82.9%). Modular bifurcated endografts were deployed in
146 patients. Endograft types were Zenith (Cook Medical
Inc, Bloomington, Ind) in 92, AneuRx (Medtronic, Min-
nesota, Minn) in 49, and Excluder (W.L. Gore & Associ-
ates, Flagstaff, Ariz.) in five patients. The other six patients
were treated with endocuffs (AneuRx, n  5; Zenith, n 
1) alone for saccular aneurysms (n  4) and pseudoaneu-
rysms (n  2).
The cumulative 5-year reimbursement for all payors per
patient was $9792, meeting 81.4% of the $12,027 in
incurred cost (Table I). This reimbursement resulted in a
Table I. Five-year cumulative postplacement costs and
reimbursement per patient
Follow-up year No. Postplacement cost Reimbursement received
1 152 $2936  $515 $2317  $216
2 109 $1693  $454 $1117  $208
3 66 $2282  $730 $2047  $628
4 54 $1769  $631 $1531  $371
5 32 $3346  $1748 $2780  $1184
Cumulative $12,027 $9792
Data are mean  standard error.net loss of $2235 for each treated patient. Medicare, capi-tated insurance, and commercial insurance provided cover-
age for 85 (56.0%), 49 (32.2%), and 18 (11.8%) patients,
respectively. Of the three payors, commercial insurance
had the highest reimbursement at $17,153 over 5 years
(Table II), and was the only payor to provide reimburse-
ment that exceeded the incurred costs of long-term surveil-
lance (Fig 1).
The cumulative 5-year charges submitted for all pa-
tients, patients with secondary procedures, and patients
without secondary procedures are presented in Figs 1, 2,
and 3, respectively. The overall reimbursement rate from all
payors over 5 years for submitted charges was 35.9% 
0.6% (Table III). The reimbursement rate for Medicare
patients was the lowest in every patient cohort.
Fifty-three secondary procedures were performed in 29
(19.1%) patients at a mean time after EVAR of 27.9  2.9
months (range 1 month to 58 months, Table IV). The
overall 5-year cumulative cost per patient with secondary
procedures was $33,314 with a reimbursement of $23,936,
which compensated 71.8% of the incurred cost (Fig 2).
Similar to the findings of the overall patient cohort, only
those patients with commercial insurance received suffi-
cient reimbursement to exceed the costs incurred from
secondary procedures.
For patients without secondary procedures (n  123,
80.9%) the 5-year cumulative cost was $4021 with an
overall reimbursement of $5851 resulting in a net gain of
$1830 per patient (Fig 3). All payors returned reimburse-
ments that exceeded the incurred costs.
DISCUSSION
This study demonstrates that current reimbursement
for long-term follow-up surveillance and needed secondary
procedures after EVAR is inadequate to cover the costs.
Importantly, the average net loss of $2235 per patient was
driven by the very poor reimbursement for needed second-
ary procedures in 19.1% of patients. Combined with the
average loss of $2100 to $3800 that may be seen with the
initial cost of EVAR,5,6 the necessity of vigilant lifetime
surveillance continues to increase the overall cost disparity
between EVAR and open surgical repair.9 This shortfall in
reimbursement for long-term surveillance after EVAR fur-
ther exacerbates the economic pressure on health care
facilities.
The initial hospital cost of EVAR exceeds that of open
surgical repair mostly due to the endograft device cost,
which can account for 47% to 78% of the total hospital cost
dependent upon the number of endograft devices, cathe-
ters, balloons, and other devices utilized for each specific
patient.5-8,14 In some cases, the reimbursement received
for EVAR was lower than that for open surgical repair.15
With postplacement surveillance, one factor for the
financial deficit may stem from the lower ratio of submitted
charges to incurred costs for those patients with secondary
procedures compared to those patients without secondary
procedures (Figs 2 and 3). Patients with secondary proce-
dures submitted an average charge 1.9-fold greater than
the incurred cost while those patients without secondary
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than the incurred cost (P  .05). While patients with
secondary procedures generated an 8.3-fold increase in
costs over those without secondary procedures ($33,314 vs
$4021, respectively, P  .05), they had a disproportion-
ately lower 3.7-fold increase in submitted charges ($62,768
Table II. Five-year cumulative postplacement reimbursem
Medicare
Follow-up year No. Reimbursement received No.
1 85 $1615  $266 49
2 60 $765  $144 35
3 34 $1640  $830 23
4 31 $1770  $629 15
5 16 $3683  $2276 9
Cumulative $9473
Data are mean  standard error.
Overall 5-year cumulative results
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Fig 1. Five-year cumulative cost, charges, and reimbursement by
payor for all patients. The values in the figure represent the
respective sum of the absolute costs, charges, and reimbursement
per patient for each payor group.
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Fig 2. Five-year cumulative cost, charges, and reimbursement by
payor for patients needing a secondary procedure. The values in
the figure represent the sum of the absolute costs, charges, and
reimbursement per patient for each payor group.vs $17,137, respectively, P  .05). Despite the modestlyhigher reimbursement rate for patients with secondary
procedures vs that of patients without secondary proce-
dures (41.7%  2.0% vs 35.1%  0.7%, respectively, P 
.05), it was insufficient to compensate for the dispropor-
tionately smaller increase in charges, consequently resulting
in an insufficient reimbursement and an overall deficit.
The factors responsible for the disparity between cost
and charges seen between the cohort of patients with and
without secondary procedures are difficult to isolate, but
are likely based on the billing and accounting practices
beyond the scope of this study. Billing regulations and
restrictions, especially in association with outpatient Medi-
care reimbursement for multiple same-day procedures and
nonallowable hospital expenses, may have accounted for
the lower reimbursement seen in those patients with sec-
ondary procedures. However, it is difficult to definitively
explain the lower charge-to-cost ratio seen in patients with
secondary procedures compared to patients without sec-
ondary procedures, or the consistently higher charges per
cost seen for patients with commercial insurance vs those
with Medicare. In addition to this disparity, the lower
reimbursement rate seen with Medicare in the majority of
the study population may have also contributed to the
overall reimbursement deficit.
Of the three factors identified as driving the overall
by individual payor
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Fig 3. Five-year cumulative cost, charges, and reimbursement by
payor for patients without secondary procedures. The values in the
figure represent the sum of the absolute costs, charges, and reim-
bursement per patient for each payor group.ent
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secondary procedure rate), decreasing the secondary pro-
cedure rate is the one factor that can be most directly
influenced by the surgeon, and will likely have the largest
impact in improving overall reimbursement.
The secondary procedure rate of 19.1% at 38.8 months
at OCF falls within the range of 12% to 28% at 36 months
published in recent literature.16-18 In the Zenith US mul-
ticenter trial, the incidence of secondary procedures was
19.5% at 48 months.17 With the current distribution of
payors, reimbursement rates, and device costs identified in
this study, a secondary procedure rate of 16.3% would be
required for the reimbursement received to equal the costs
of long-term surveillance after EVAR at OCF.
Further improvements in technical skill, patient selec-
tion, endograft device durability, and endograft manufac-
turing to decrease the incidence of endograft failure, mi-
gration, or endoleak will all be instrumental in decreasing
the rate of secondary procedures and eliminating a deficit
between reimbursement and cost. Improved accuracy in
documentation resulting in more accurate billing may pro-
Table III. Five-year cumulative mean reimbursement rate
All patientsa
n  152
All patients 35.9%  0.6%
Medicare 31.6%  0.7%
Capitated insurance 40.7%  1.1%
Commercial insurance 41.8%  2.1%
Data are mean  standard error.
aThe reimbursement rate was similar between capitated insurance and comm
(P  .05).
bThe reimbursement rate of each payor was significantly different from each
cStatistically significant (P  .05) vs the respective secondary procedure gro
Table IV. Secondary procedures
Procedure Total Mean costa
Endograft explant/EABb 2 $59,700  $6690
Iliac limb placement/AECc 1 $30,511
Open conversion (delayed) 4 $22,130  $3240
Aorto-uni-iliac device 1 $21,717
Iliac endocuff 6 $13,498  $2354
Aortic endocuff 5 $9027  $2112
Femoral-femoral bypass 1 $8505
Laparoscopic IMA ligation 1 $8302
Thrombolysis 2 $7697  $743
PTA  stent 2 $5333  $346
Translumbar glue embolization 3 $5020  $796
Coil microembolization 4 $4802  $474
Diagnostic angiogram 20 $2771  $391
Abscess drainage 1 $1560
EAB, Extra anatomic bypass; AEC, aortic endocuff; IMA, inferior mesen-
teric artery; PTA, percutaneous transluminal angioplasty.
aData are mean  standard error.
bOne procedure was staged, with the costs of both procedures combined.
cStaged placement of iliac limb after the initial endograft device malfunc-
tioned.vide a greater degree of reimbursement.A shift in the surveillance protocol to monitoring with
the use of abdominal ultrasound imaging instead of CT
scan19 may decrease the cost of long-term surveillance. Use
of the EndoSure AAA Wireless Pressure Measurement Sys-
tem (CardioMEMS, Atlanta, Ga) within the aneurysmal sac
during EVAR as a surveillance tool to identify an en-
doleak20 is another potential alternative to CT scans. How-
ever, it is unknown whether this surveillance regimen
would be cost effective, as the initial expense of the pressure
sensor is $3500, and the device reader cost is $25,000.
While these methods may result in potential cost savings of
long-term surveillance, this may not translate to an increase
in reimbursement. In most health care settings, reimburse-
ment for CT scanning exceeds the cost, resulting in an
incremental profit. A shift away from routine use of CT
scanning may actually increase the overall net loss for
surveillance after EVAR.
Limitations. Several limitations exist in this study.
First, the analysis of costs and reimbursement received at a
single institution is not universally applicable. Multiple
factors will influence the hospital-specific reimbursement
rate, including and not limited to geographic location, the
local labor market, and the population demographic served
by the hospital. In addition, billing and accounting meth-
ods will likely differ between institutions, and the base
contract rates negotiated by the hospital with each individ-
ual payor varies annually and could even vary between
hospitals within the same geographic region.
The relatively small sample size of patients with second-
ary procedures may have limited the ability for meaningful
statistical analysis due to the low power, and may explain
why much of the differences in the cost, charge, and reim-
bursement in this patient cohort failed to reach statistical
significance.
Secondly, the distribution of patient payors at OCF is
not reflective of the national average. Patients with Medi-
care comprised 56.0% of the patients undergoing EVAR at
OCF. Nationally, 76.0% to 82.2% of patients undergoing
EVAR had Medicare coverage within the same time pe-
riod.21 The lower reimbursement rate byMedicare vs com-
mercial insurance seen in this study is particularly concern-
ing for hospitals whose payor population more closely
tive to charge
Secondary procedureb No secondary procedurea
n  29 n  123
41.7%  2.0% 35.1%  0.7%c
35.3%  2.3% 31.2%  0.7%
42.0%  2.0% 40.4%  1.2%
49.5%  2.6% 38.3%  2.6%c
nsurance (P .05) but were both significantly greater than that ofMedicare
r (P  .05).s rela
ercial iresembles the national average.
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EVAR patients at OCF obtained complete follow-up of all
scheduled outpatient visits and surveillance imaging per
protocol. The calculated cost and reimbursement pre-
sented in this study does not represent all of the potential
costs and reimbursement of a patient after EVAR. Instead
the data reflects the values to be expected from a “real-
world” patient population.
Lastly, there may also be device-specific costs unique to
the brand of endograft used in EVAR. Other institutions
utilizing different endograft devices may experience differ-
ent rates of secondary procedures and subsequent variables
in cost and reimbursement.
CONCLUSION
Reimbursement for the cost of long-term surveillance
after EVAR is inadequate. Although the majority of pa-
tients was free from secondary procedures and generated a
profit, a net deficit created by the minority of patients
requiring secondary procedures resulted in the net loss of
income post EVAR.
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